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To investigate the eﬃcacy of phage supplementation in reducing pathogen numbers, mice were treated via oral gavage with
a Listeria monocytogenes phage preparation (designated ListShield) before being orally infected with L. monocytogenes.T h e
concentrations of L. monocytogenes in the liver, spleen, and intestines were signiﬁcantly lower (P<. 05) in the phage-treated
than in the control mice. Phage and antibiotic treatments were similarly eﬀective in reducing the levels of L. monocytogenes in the
internal organs of the infected mice. However, the signiﬁcant weight loss detected in the control and antibiotic-treated groups was
not observed in the infected, ListShield-treated mice. Long-term (90 days), biweekly treatment of uninfected mice with ListShield
did not elicit detectable changes in the microbiota of their large intestines or deleterious changes in their health. Our data support
the potential feasibility of using bacteriophages to control proliferation of L. monocytogenes in mice without aﬀecting commensal
microbiota composition.
1.Introduction
Food borne bacterial pathogens remain a major health
threat. Beyond reducing pathogen load at the source and
in the ﬁnal product, few measures are currently available
to protect the human host. Side eﬀects associated with
long-term antibiotic treatment and the danger of emerging
novel antibiotic resistance strains make an antibiotic-based
preventionregimenunfeasible.Incontrast,promisingeﬀorts
arenowbeingdirectedtowardsutilizingourowncommensal
microbiota to improve resistance to pathogens. The conven-
tional approach aims at reshaping microbiota composition
towards beneﬁcial bacteria by adding live probiotic bacteria
and/or by enhancing their growth through addition of pre-
biotic supplements [1]. An alternative approach for shaping
overallmicrobiotacompositionaimedatreducingdetrimen-
tal and potentially pathogenic bacteria by means of speciﬁc
bacteriophages has to date received much less attention.
The human gastrointestinal (GI) tract is colonized by an
abundant and diverse microbiota that plays a signiﬁcant role
in mucosal protection, regulation of GI immune tolerance,
digestion of complex macromolecules including mucus and
ﬁber, and vitamin K synthesis [2, 3]. Numerous factors (e.g.,
age, antibiotic treatment, diet, psychological and physical
stress, hormone levels, etc.) may lead to physiological
disturbances in the gut’s microbiota [4]. Such alterations
may contribute to many chronic and degenerative diseases,
including Crohn’s disease, ulcerative colitis, rheumatoid
arthritis, irritable bowel syndrome, inﬂammatory bowel
disease, and other “intestinal dysbioses” [5, 6]. Modiﬁcation
of gut microbiota by pre- and probiotics has been shown
to modify risk for a variety of diseases, modulate of cell
proliferation, and decrease serum cholesterol [7, 8].
Bacteriophages (phages) are viruses that attach to their
speciﬁc bacterial hosts and kill them by sequential inter-
nal replication and lysis. Phages are the most ubiquitous2 International Journal of Microbiology
organisms on Earth (their total number has been estimated
to be 1030 to 1032), and they are believed to play a key
role in establishing microbial balance in every ecosystem in
which they are present [9]. Phages are abundant in saltwater,
freshwater,soil,plants,andanimals,andtheyfrequentlyhave
been isolated from drinking water [10–17], and from a wide
range of food products, including ground beef, pork sausage,
chicken, farmed freshwater ﬁsh, common carp and marine
ﬁsh, oil sardines, raw skim milk, and cheese [18–23]. In
humans, prodigious numbers of phages “colonize” the GI
tract, and they have been isolated from the skin, mouth,
vagina, urine, and feces [24, 25]( f o rar e v i e w ,s e e[ 26]).
The use of phages in humans is very safe, as summarized
in numerous recent review articles [26–34]. Thus, we
hypothesized that phage administration might be safe and
eﬀective means for reducing or eliminating food borne and
waterborne bacterial pathogens in the gut without altering
the normal gut’s microbiota; thereby, eliciting signiﬁcantly
fewer deleterious side eﬀects compared to antibiotics. If our
hypothesis is proven to have merit, regular administration
of bacteriophages (e.g., similar to a probiotic preparation
which is part of the daily diet) may in the future provide
a natural, safe, and gentle means for maintaining healthy
gut microbiota and protecting against speciﬁc food borne
and waterborne pathogens. The current report presents the
results of our proof-of-concept, in vivo studies examining a
L. monocytogenes speciﬁc bacteriophage preparation’s eﬀect
on the (i) concentrations of L. monocytogenes in internal
organs and associated health eﬀects in experimentally-
infected mice, and (ii) overall health of mice including
normalgutmicrobiotacompositionafterlongtermexposure
to our phage preparation.
2.MaterialsandMethods
2.1. Phage Preparation. ListShield (formerly LMP-102), a
L. monocytogenes-speciﬁc phage preparation developed by
Intralytix, Inc., was used during our studies as the prototype
phage-based probiotic preparation. ListShield is a mix-
ture/cocktail of six naturally occurring bacteriophages with
strong lytic potency against L. monocytogenes. ListShield has
been approved by the Food and Drug Administration as a L.
monocytogenes-speciﬁc food additive for ready-to-eat meats
(21 CFR §172.785), and by the Environmental Protection
Agency as an environmental decontaminant for use in
various food processing plants and establishments (EPA
registration no. 74234-1). ListShield lots no. 0108B070117
and 0108D160161 were used during our studies.
2.2. Bacterial Strains. L. monocytogenes strain Lm370 was
used to experimentally infect mice. It is a nalidixic acid-
resistant mutant of ATCC strain 49594 derived from the
Scott A strain. The mutant was selected by serially passaging
ATCC strain 49594 on MOX agar plates supplemented
with increasing concentrations of nalidixic acid. The strain
underwent ≤8 serial passages before it was determined to
be nalidixic acid-resistant at a concentration of ca. 50ng/ml.
Lm370 also is sensitive to ampicillin and ListShield. Its
sensitivity to ampicillin was determined by a standard
disk diﬀusion method, and its sensitivity to ListShield was
determined as described below. The strain was stored frozen
(−80◦C) in 30% glycerol/70% LB broth, plated on MOX
agar prior to use, and grown in LB broth (30◦C, overnight)
before being administered to mice by oral gavages. The
MOX agar and LB broth used to grow the bacterium were
supplemented with nalidixic acid (50ng/ml). The following
21 non-L. monocytogenes strains were used to conﬁrm the in
vitrospeciﬁcityofListShield:twoEnterococcusfaecalisstrains
(1) ATCC 11823, and (2) ATCC 19433; eight E. coli strains
(1) ATCC 700728, (2) ATCC 35321, (3) ATCC 35322, (4)
ATCC 35335, (5) ATCC 35342, (6) ATCC 35343, (7) ATCC
35351, (8) ATCC 35352; one Shigella sonnei strain ATCC
9290; four Pseudomonas aeruginosa strains (1) ATCC 15692,
(2) ATCC 51674, (3) ATCC 43390, (4) ATCC 39324; and
six Salmonella enterica subsp. enterica strains, including (1-
2) serovar Typhimurium strains ATCC 19585 and ATCC
13311, (3) serovar Gallinarum strain ATCC 9184, (4) serovar
Newport strain ATCC 6962, (5) serovar Enteritidis strain
ATCC 13076, and (6) serovar Paratyphi B strain ATCC
10719.
2.3. Determining the In Vitro Speciﬁcity of Phage Preparation.
The in vitro speciﬁcity of ListShield was conﬁrmed by
characterizing its ability to lyse 21 strains of the above-
mentioned bacterial species other than L. monocytogenes.
Lytic activity was detected with a classical spot-testing
technique [35], by incubating bacterial lawns spotted with
aliquots of diluted phage preparations (104 PFU/ml) and
examining the lawns for zones of lysis.
2.4. In Vivo Studies. Inbred C57BL/6J mice were obtained
from Harlan (Harlan laboratories, Indianapolis, IN), accli-
mated to the laboratory environment for at least 3 days after
arrival, and fed ad libitum with Harlan chow 7912 (Harlan
laboratories, Indianapolis, IN) and water. The studies were
conducted at the University of Florida (UFL), according to
a protocol (no. FO97) approved by the UFL’s Institutional
Animal Care and Use Committee. The in vivo studies were
performed as short-term (7 days) and long-term (90 days)
experiments.
At the start of the short-term (7 days) study, each mouse
was weighed and randomly assigned to three experimental
groups: Group 1 (15 mice, the PBS control group) received
phosphate-buﬀered saline (PBS, pH 7.4) daily for 3 days
before and after challenge (ca. 105 colony-forming units
[CFU]) with strain Lm370; Group 2 (20 mice, the ListShield
test group) was treated with ListShield (105 PFU) daily for
3 days before and after challenge; and Group 3 (10 mice,
the antibiotic test group) received PBS daily for 3 days
prechallenge, and was treated with one dose of ampicillin
(25mg/g)15minpostchallenge.Alltreatmentsandchallenge
doses of bacteria were administered by oral gavage in 0.1ml
PBS. After being weighed again, each mouse was sacriﬁced
on day 7 by CO2 inhalation followed by cervical dislocation.
Aftersacriﬁce,(i)theleftlowerlobeoftheliver,(ii)theentire
spleen, (iii) a 5-cm-long section of the small intestine, (iv)International Journal of Microbiology 3
the cecum, and (v) fecal matter from the large intestine of
each mouse were weighed and placed in separate aliquots
(5ml) of cold PBS and their concentrations of strain Lm370
were determined as described below. Also, fecal matter was
frozen and subsequently analyzed to characterize microbiota
proﬁles (see below). During the short-term study body
weight was measured daily.
For the long-term (90 days) study, each mouse was
weighed and randomly assigned to two experimental groups
(15 mice/group): Group 1 (test mice) received ListShield
biweekly, in their drinking water, at a concentration of ca.
105 PFU/ml; and Group 2 (control mice) received drinking
water containing PBS biweekly. Five mice in each group were
sacriﬁced by CO2 inhalation followed by cervical dislocation
on days 30, 60, and 90 after their ﬁrst ingestion of ListShield.
Final body weight was measured before liver, spleen, and
small intestinal tissues were removed and examined for
histopathological changes. Also, specimens of unclotted
blood and fecal matter were obtained on day 90 from each
mouse. The former were analyzed for their concentrations
of various white blood cells (WBC), and the latter were
frozen and subsequently analyzed to characterize microbiota
proﬁles (see below).
2.5. L. monocytogenes Enumeration and Phage Titers. Tissues
ofinternalorgansandfecalmatterweregroundinDulbecco’s
PBS (pH 7.0) with a tissue homogenizer, and aliquots
(0.1ml) of each preparation were spread, in duplicate,
on MOX agar plates supplemented with nalidixic acid
(50ng/ml). The plates were incubated (30◦C, 48h), the
numberofviableL.monocytogeneswasestimatedbystandard
colony counting, and the concentrations were expressed
as the number of CFU/g of specimen. Concentrations of
ListShield phages in the samples were determined by ﬁltering
the samples through 0.45µm ﬁlters and by analyzing the
ﬁltrates using standard plague counting assay [36].
2.6. Enumeration of WBC. The concentrations of granulo-
cytes (neutrophils, basophils, and eosinophils) and agran-
ulocytes (lymphocytes and monocytes) were determined in
blood samples obtained from mice at the end of the long-
term study. The analysis was performed in the animal facility
under supervision of a veterinarian pathologist.
2.7. Microbiota Denaturing Gradient Gel Electrophoresis
(DGGE) Proﬁles. Bacterial genomic DNA was isolated from
the large intestinal contents as previously described [37]. A
457-bp fragment from the V6 to V8 region of the bacterial
16S rDNA gene was ampliﬁed with primers U968-GC (5 
CGC CCG GGG CGC GCC CCG GGC GGG GCG GGG
GCACGGGGGGAACGCGAAGAACCTTAC)andL1401
(5 GCGTGTGTACAAGACCC), as described by Zoetendal
et al. [38]. DGGE was performed in an 8% (wt/vol)
polyacrylamide gel with a denaturing gradient ranging from
40% to 50% at the top and bottom of the gel, respectively
(100% denaturing conditions were deﬁned as 7M urea and
40% formamide). After electrophoresis (16h, 65V, 60◦C),
the gels were stained with SYBER Green (Novex, San Diego,
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Figure 1: Mean body weights of mice infected with L. mono-
cytogenes and treated with PBS, ListShield, and ampicillin. The
results shown are for the days postchallenge with strain Lm370. The
standard deviations are indicated with brackets.
CA) and scanned/analyzed with Quantity One and Diversity
Database software (Bio-Rad, Hercules, CA).
2.8. Statistical Analysis. The signiﬁcance of diﬀerences in
the L. monocytogenes concentrations in the test and control
groups of mice was determined in MS Exel using two-
tailed t-tests. The relatedness of the microbiota proﬁles was
calculated using Pearson correlation coeﬃcients and the
gel analysis software package Diversity Database (Bio-Rad,
Hercules, CA). Microbiota diversity was determined using
the Shanon Wiener index and the Simpson diversity index.
3. Results
An animal model closely resembling human listeriosis is
currently not available. Thus, we used a simpliﬁed model
in which mice were challenged by oral gavage with a single
dose of L. monocytogenes strain Lm370. L. monocytogenes
persistedintheanimalsforatleast3daysandinalluntreated
mice translocated to spleen and liver. Out of 45 mice two
mice in the PBS-treated group, two mice in the ampicillin-
treatedgroup,andonemouseintheListShield-treatedgroup
died prematurely, likely from stomach puncture during oral
gavage. These mice were excluded from the analysis. Thus,
data from 13 mice in the PBS-treated/control group, 8 mice
in the ampicillin-treated test group, and 19 mice in the
ListShield-treated test group were retained in the short-term
study.
Bodyweightdidnotdiﬀerbetweenthegroupsatthetime
of randomization. Within three days of challenge with L.
monocytogenes mice in the PBS treated and in the ampicillin
treatedgroupslostupto10%oftheirbodyweight(Figure 1).
In contrast, mice in the ListShield treated group maintained
their body weight; the diﬀerence in weight loss between
these groups was statistically signiﬁcant (P<. 05). The body4 International Journal of Microbiology
Table 1: Tissue histology and blood chemistry in the two groups (N = 5 mice/group), N = normal, I = inﬁltrate, D = dermatitis.
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Figure 2: Recovery of L. monocytogenes from experimentally-
infected mice treated with PBS, ListShield, and ampicillin. The
bacterial concentrations are expressed as the number of CFU/g of
specimen.Theresultsshownarefor3dayspostchallengewithstrain
Lm370. The standard deviations are indicated with brackets.
weight loss in mice treated with PBS and ampicillin was due
todiarrheathatwasobservedshortlyafterbacterialchallenge
and at necropsy. Thus, we found that treatment with our L.
monocytogenes-speciﬁc phage preparation (ListShield), but
not with PBS or ampicillin, signiﬁcantly reduced diarrhea
associated weight loss.
Allofthechallengedmiceweresacriﬁcedonday7(4days
postchallenge) and the concentrations of strain Lm370 were
determined in their livers, spleens, and intestines. The levels
of Lm370 in all of the examined specimens were signiﬁcantly
lower (P<. 05) in the ListShield- and ampicillin-treated
groups than in the PBS treated mice (Figure 2). The Lm370
concentrationsintissuesfromtheampicillin-andListShield-
treatedmiceweresimilar(diﬀerencenotsigniﬁcant;P>. 05),
indicating that both treatments were eﬀective in reducing L.
monocytogenes colonization/infection in this mouse model.
We monitored persistence of bacteriophage in fecal pellets
and cecal contents. However, phage titers were below detec-
tion limits of the assay suggesting that phage ampliﬁcation in
the gut environment was limited.
At necropsy, we observed that the mice treated with
ampicillin, but not those treated with ListShield, exhibited
watery large intestinal contents and enlarged ceca. This
observation suggests that the broad-spectrum antibiotic
(ampicillin), while reducing the L. monocytogenes levels,
deleteriously aﬀected normal gut microbiota, which resulted
in the diarrhea and weight loss we observed. Because one
dose of ampicillin was suﬃcient to remove most challenge
bacteria, we only administered the antibiotic once after
challenge. Importantly, the detrimental eﬀects of ampicillin
treatment on the GI microbiota of mice were still more
obvious than in the mice receiving three postchallenge doses
of ListShield. In order to further evaluate this possibility, we
used 16S rRNA-based DGGE to characterize and compare
the microbiota proﬁles in the intestinal contents of the
three groups. The intensity of some DGGE bands was
increased in the ampicillin-treated group, which suggests
that ampicillin-treatment caused overgrowth of some of
the normal intestinal bacteria. However, this suggestive
diﬀerence in overall microbiota diversity was not statistically
signiﬁcant when determined using Shannon Wiener and
Simpson diversity indexes (P>. 05).
To determine potential side eﬀects of long-term phage
administration, we performed a 90-day-long study of List-
Shield (supplied via drinking water) on overall health and
large intestinal microbiota of mice not infected with L.
monocytogenes. On days 0, 30, 60, and 90 of the long-term
study, the mean body weight of the mice comprising the
ListShield test group was not signiﬁcantly diﬀerent from that
of the mice in the PBS control group. After 90 days, the
white blood cell concentrations in the ListShield test mice
were not signiﬁcantly diﬀerent from those of the PBS control
mice (Figure 3). Also, blood chemistry and tissue pathology
did not show gross abnormalities (Table 1). We did detect a
minor increase in lymphocyte inﬁltrate into the duodenum
and mild dermatitis in the LMP-102 group. These ﬁndings
indicate little changes in overall health.
The lytic activity of ListShield was limited to the targeted
L. monocytogenes strains, and the preparation did not lyse
in vitro any of the 21 strains of other bacterial species we
examined. Our in vivo data were in agreement with these
observations: oral administration of ListShield did not alter
the normal diversity of the GI tract microbiota. Although
the DGGE analysis did reveal some diﬀerences between the
DGGE band proﬁles of the fecal microbiota in the ListShield
group; overall diversity in the PBS control mice was similar
(Figure 4).
4. Discussion
The rationale for our studies was based on the hypothesis
that regular, long-term ingestion of bacteriophages (e.g.,
similar to a probiotic preparation consumed as part of the
daily diet) can be safely used to signiﬁcantly reduce the
levels of speciﬁc bacterial pathogens in the mammalian
gastrointestinal (GI) tract and reduce translocation toInternational Journal of Microbiology 5
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Figure 3: Concentrations of various white blood cells (WBC) in
uninfected mice after long-term (90 days) ingestion of ListShield.
The standard deviations are indicated with brackets. NE: neu-
trophils; LY: lymphocytes; MO: monocytes; EO: eosinophils; BA:
basophils.
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Figure 4: DGGE proﬁles of the microbiota in fecal specimens
obtained from uninfected mice after long-term (90 days) ingestion
of ListShield. S: standards (DNA from mix of 16S rRNA clones);
PBS: proﬁles of the fecal microbiota in PBS control mice; LMP-102:
proﬁles of the fecal microbiota in ListShield test mice.
internal organs. The key diﬀerence between the conventional
approach used for bacteria-based probiotics and our current
approach for phage-based preparations is that the former
introduces nonpathogenic bacteria into the GI tract in
order to improve immune balance colonization resistance;
whereas, the latter directly removes speciﬁc pathogenic
bacteria from the GI tract.
The animal model used during our studies does not
closely mimic human listeriosis; therefore, extrapolations
about the potential comparable eﬃcacy of ListShield and
ampicillin in preventing and treating human disease cannot
be made at this time. ListShield was administered at a
high dose soon after infection with Listeria. Also, numbers
of Listeria in the GI tract of a human host would be
low making maintenance of an infectious cycle diﬃcult
for phage propagation. We observed a large variation in
pathogen load among individual mice possibly masking a
statistically signiﬁcant increase in L. monocytogenes in spleen
tissue in ListShield group compared to the ampicillin group
(Figure 2). Nevertheless, our data do (i) suggest that oral
administration of ListShield can signiﬁcantly reduce the
number of viable L. monocytogenes in the GI tract and
the reticuloendothelial system (e.g., the liver and spleen) of
orally infected mice, and (ii) support our general hypothesis
that probiotic-type phage administration is capable of sig-
niﬁcantly reducing in vivo colonization by their pathogenic
bacterial hosts.
The observation that ListShield did not lyse any of
the non-L. monocytogenes strains was expected given the
known high speciﬁcity of bacteriophages towards their host
strains. Our data provided further support to this idea. In
the same context, our microbiota analysis did not reveal
signiﬁcantdiﬀerencesbetweentheDGGEproﬁlesofthefecal
microbiota in the ListShield test mice and the PBS control
mice. Although the sensitivity of DGGE was not optimal the
data we obtained during our in vitro sensitivity examination
of ListShield, and the short-term and long-term in vivo
studies, suggest that oral ingestion of ListShield aﬀects the
overall composition of the large intestine’s microbiota less
than does ampicillin ingestion. Overall, our results suggest
that (i) using bacteriophages may be a similarly eﬀective
but gentler approach than using antibiotics for reducing L.
monocytogenescolonization/translocation,and(ii)ListShield
can be administered to mice without any detectable side
eﬀects over a relatively long period of time (at least 90 days).
Our approach of using phages as probiotics for speciﬁcally
targeting bacterial pathogens in the GI tract may have some
important public health implications, and it may provide
an eﬀective and gentle means for preventing or reducing
the severity of disease caused by L. monocytogenes and,
potentially, other foodborne or waterborne pathogens that
have an oral portal of entry and require short- or long-term
colonization of the GI tract in order to cause disease.
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